Skip to Content Skip to Search

GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials

For media and investors only

Issued: London, UK - 19 June 2020

Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019

GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system. 

The study initiation follows promising preclinical results which demonstrated the beneficial effect of GSKs pandemic adjuvant for the SCB-2019 vaccine candidate, with high neutralizing antibody levels elicited in multiple animal species.

Preliminary safety and immunogenicity results for the Phase 1 study are expected in August 2020. In parallel, the planning for a global Phase 2b/3 vaccine efficacy trial has begun, with initiation targeted later in 2020.

The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of protein required per dose, allowing more vaccine doses to be produced and made available to more people.

GSK has announced several scientific collaborations globally to develop adjuvanted COVID-19 vaccines. GSK expects further studies to begin across the range of its collaborations, including with Sanofi, later this year. 

Thomas Breuer, Chief Medical Officer, GSK Vaccines, said:

“Our deliberate approach is to combine our proven pandemic adjuvant technology with protein-based COVID-19 vaccine candidates from several collaborators. We believe this holds the promise to produce vaccines at scale, potentially benefiting billions of people. We are encouraged by the pre-clinical data of this adjuvanted COVID-19 vaccine candidate from Clover and look forward to reviewing the data from this first trial. If this trial is successful, we hope to be in a position to move into more advanced trials later in the year.”

Clover Biopharmaceuticals is a China-based, global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. The research collaboration between GSK and Clover to develop a COVID-19 vaccine candidate was announced on 24th February 2020.

About the study

The Phase I clinical trial is a randomized, double-blind, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels. Each SCB-2019 dose level will be evaluated with and without adjuvant. The study is being conducted at Linear Clinical Research in Perth, Australia and will enrol approximately 90 healthy adult participants and 60 healthy elderly participants. The trial and Clover’s COVID-19 vaccine program is being supported by the funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2019.